Future work should include a larger sample size, a longer study period and be paired with other tests of other cognitive domains to assess whether there will be an improvement in the accuracy of tau-PET as a prognostic marker for preclinical Alzheimer’s disease. The gene discussed is MAPT; the disease is Alzheimer disease.